Tesofensine
TESOTriple monoamine reuptake inhibitor.
Also known as: NS2330
Overview
Tesofensine is a triple monoamine-reuptake inhibitor studied in appetite-regulation and weight-management research.
An orally active triple monoamine reuptake inhibitor (noradrenaline, dopamine, serotonin) studied for appetite suppression. Originally investigated for neurodegenerative conditions, it showed notable weight effects in obesity trials via central appetite pathways rather than incretin signaling.
Inhibits reuptake of noradrenaline, dopamine, and serotonin, studied for appetite suppression and increased satiety signaling.
Molecular information
NS2330 — a phenyltropane small molecule; not a peptide, hence oral stability.
Pharmacokinetics
Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.
Research applications
- Appetite-regulation research
- Monoamine-signaling studies
- Energy-balance investigations
Research protocols
Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.
Observed effects timeline
Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.
Week 1–2
Onset of appetite suppression; the very long half-life means levels accumulate over weeks.
Week 4–12
Progressive weight change reported in obesity-research cohorts.
Ongoing
Slow clearance after discontinuation due to extended half-life.
Research compatibility
Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.
Semaglutide
Different appetite mechanisms; combined effects monitored in research.
Stimulants/MAOIs
Monoaminergic overlap raises cardiovascular/serotonergic risk.
5-Amino-1MQ
Co-studied in metabolic contexts.
Quality indicators
Consistent oral form
Research material is typically a capsule or tablet; verify the labeled concentration.
Dry storage
As a stable small molecule, it does not require cold-chain handling like peptides.
Slight clumping
Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.
Collapsed or melted appearance
Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.
Cloudy after reconstitution
Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.
Reported observations & safety
Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.
- Elevated heart rate, blood pressure, dry mouth, and sleep disturbance are commonly reported (monoaminergic activity).
- Cardiovascular monitoring is standard in research designs given the stimulant-like profile.
References & further reading
Tesofensine for obesity (Lancet, 2008)
Phase 2 trial reporting dose-dependent weight reduction with the triple monoamine reuptake inhibitor over 24 weeks.
View studyTopics
This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.
Substantial peer-reviewed research across multiple models.
This compound is part of our educational reference and is not currently stocked. Browse the catalogue for available research-grade peptides.
Browse catalogue